Mycophenolate mofetil for the treatment of primary sclerosing cholangitis

Jayant A. Talwalkar, Paul Angulo, Jill C. Keach, Janice L. Petz, Roberta A. Jorgensen, Keith D. Lindor

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology. Despite advances in understanding the pathophysiology underlying this disorder, no effective medical therapy has been identified for halting disease progression. The aim of this investigation was to determine the safety and estimated efficacy of mycophenolate mofetil (MMF) for the treatment of PSC. Thirty patients with PSC received MMF 1 g daily to a maximum of 3 g daily for 1 yr. Liver tests were determined at 3-month intervals with the Mayo risk score calculated at baseline and at the end of therapy. Twenty-three (77%) patients completed 1 yr of therapy. Significant but clinically marginal improvement in serum alkaline phosphatase level after 1 yr of therapy was observed (1135 ± 581 U/L vs 912 ± 463 U/L, p = 0.02). No other significant changes in liver biochemistries or Mayo risk score was observed. Seven patients (23%) discontinued MMF due to adverse events possibly related to therapy. Adverse reactions resolved spontaneously or with dose reduction in 10 (33%) patients. One patient developed pancreatitis, bacterial cholangitis, and sepsis during the eighth month of MMF therapy. No patient developed cytopenia on therapy. In conclusion, MMF does not appear to have clinically important benefits for PSC despite being tolerated by most patients. The results of this pilot study do not support further study of MMF as a single agent in the treatment of PSC.

Original languageEnglish (US)
Pages (from-to)308-312
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume100
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Mycophenolic Acid
Sclerosing Cholangitis
Therapeutics
Cholangitis
Liver
Pancreatitis
Biochemistry
Alkaline Phosphatase
Disease Progression
Liver Diseases
Sepsis
Safety

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Talwalkar, J. A., Angulo, P., Keach, J. C., Petz, J. L., Jorgensen, R. A., & Lindor, K. D. (2005). Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. American Journal of Gastroenterology, 100(2), 308-312. https://doi.org/10.1111/j.1572-0241.2005.40484.x

Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. / Talwalkar, Jayant A.; Angulo, Paul; Keach, Jill C.; Petz, Janice L.; Jorgensen, Roberta A.; Lindor, Keith D.

In: American Journal of Gastroenterology, Vol. 100, No. 2, 02.2005, p. 308-312.

Research output: Contribution to journalArticle

Talwalkar, JA, Angulo, P, Keach, JC, Petz, JL, Jorgensen, RA & Lindor, KD 2005, 'Mycophenolate mofetil for the treatment of primary sclerosing cholangitis', American Journal of Gastroenterology, vol. 100, no. 2, pp. 308-312. https://doi.org/10.1111/j.1572-0241.2005.40484.x
Talwalkar, Jayant A. ; Angulo, Paul ; Keach, Jill C. ; Petz, Janice L. ; Jorgensen, Roberta A. ; Lindor, Keith D. / Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. In: American Journal of Gastroenterology. 2005 ; Vol. 100, No. 2. pp. 308-312.
@article{fef78d497a9b436e8539ce3abfc29b7f,
title = "Mycophenolate mofetil for the treatment of primary sclerosing cholangitis",
abstract = "Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology. Despite advances in understanding the pathophysiology underlying this disorder, no effective medical therapy has been identified for halting disease progression. The aim of this investigation was to determine the safety and estimated efficacy of mycophenolate mofetil (MMF) for the treatment of PSC. Thirty patients with PSC received MMF 1 g daily to a maximum of 3 g daily for 1 yr. Liver tests were determined at 3-month intervals with the Mayo risk score calculated at baseline and at the end of therapy. Twenty-three (77{\%}) patients completed 1 yr of therapy. Significant but clinically marginal improvement in serum alkaline phosphatase level after 1 yr of therapy was observed (1135 ± 581 U/L vs 912 ± 463 U/L, p = 0.02). No other significant changes in liver biochemistries or Mayo risk score was observed. Seven patients (23{\%}) discontinued MMF due to adverse events possibly related to therapy. Adverse reactions resolved spontaneously or with dose reduction in 10 (33{\%}) patients. One patient developed pancreatitis, bacterial cholangitis, and sepsis during the eighth month of MMF therapy. No patient developed cytopenia on therapy. In conclusion, MMF does not appear to have clinically important benefits for PSC despite being tolerated by most patients. The results of this pilot study do not support further study of MMF as a single agent in the treatment of PSC.",
author = "Talwalkar, {Jayant A.} and Paul Angulo and Keach, {Jill C.} and Petz, {Janice L.} and Jorgensen, {Roberta A.} and Lindor, {Keith D.}",
year = "2005",
month = "2",
doi = "10.1111/j.1572-0241.2005.40484.x",
language = "English (US)",
volume = "100",
pages = "308--312",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Mycophenolate mofetil for the treatment of primary sclerosing cholangitis

AU - Talwalkar, Jayant A.

AU - Angulo, Paul

AU - Keach, Jill C.

AU - Petz, Janice L.

AU - Jorgensen, Roberta A.

AU - Lindor, Keith D.

PY - 2005/2

Y1 - 2005/2

N2 - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology. Despite advances in understanding the pathophysiology underlying this disorder, no effective medical therapy has been identified for halting disease progression. The aim of this investigation was to determine the safety and estimated efficacy of mycophenolate mofetil (MMF) for the treatment of PSC. Thirty patients with PSC received MMF 1 g daily to a maximum of 3 g daily for 1 yr. Liver tests were determined at 3-month intervals with the Mayo risk score calculated at baseline and at the end of therapy. Twenty-three (77%) patients completed 1 yr of therapy. Significant but clinically marginal improvement in serum alkaline phosphatase level after 1 yr of therapy was observed (1135 ± 581 U/L vs 912 ± 463 U/L, p = 0.02). No other significant changes in liver biochemistries or Mayo risk score was observed. Seven patients (23%) discontinued MMF due to adverse events possibly related to therapy. Adverse reactions resolved spontaneously or with dose reduction in 10 (33%) patients. One patient developed pancreatitis, bacterial cholangitis, and sepsis during the eighth month of MMF therapy. No patient developed cytopenia on therapy. In conclusion, MMF does not appear to have clinically important benefits for PSC despite being tolerated by most patients. The results of this pilot study do not support further study of MMF as a single agent in the treatment of PSC.

AB - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology. Despite advances in understanding the pathophysiology underlying this disorder, no effective medical therapy has been identified for halting disease progression. The aim of this investigation was to determine the safety and estimated efficacy of mycophenolate mofetil (MMF) for the treatment of PSC. Thirty patients with PSC received MMF 1 g daily to a maximum of 3 g daily for 1 yr. Liver tests were determined at 3-month intervals with the Mayo risk score calculated at baseline and at the end of therapy. Twenty-three (77%) patients completed 1 yr of therapy. Significant but clinically marginal improvement in serum alkaline phosphatase level after 1 yr of therapy was observed (1135 ± 581 U/L vs 912 ± 463 U/L, p = 0.02). No other significant changes in liver biochemistries or Mayo risk score was observed. Seven patients (23%) discontinued MMF due to adverse events possibly related to therapy. Adverse reactions resolved spontaneously or with dose reduction in 10 (33%) patients. One patient developed pancreatitis, bacterial cholangitis, and sepsis during the eighth month of MMF therapy. No patient developed cytopenia on therapy. In conclusion, MMF does not appear to have clinically important benefits for PSC despite being tolerated by most patients. The results of this pilot study do not support further study of MMF as a single agent in the treatment of PSC.

UR - http://www.scopus.com/inward/record.url?scp=13944277732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13944277732&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2005.40484.x

DO - 10.1111/j.1572-0241.2005.40484.x

M3 - Article

VL - 100

SP - 308

EP - 312

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -